KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $36.6 million.

  • Emergent BioSolutions' Accumulated Expenses fell 4218.01% to $36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.6 million, marking a year-over-year decrease of 4218.01%. This contributed to the annual value of $56.1 million for FY2024, which is 2429.15% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Accumulated Expenses is $36.6 million, which was down 4218.01% from $31.5 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Accumulated Expenses registered a high of $88.7 million during Q4 2021, and its lowest value of $24.7 million during Q1 2025.
  • For the 5-year period, Emergent BioSolutions' Accumulated Expenses averaged around $62.4 million, with its median value being $63.3 million (2024).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 1772.15% in 2022, then plummeted by 5277.36% in 2025.
  • Emergent BioSolutions' Accumulated Expenses (Quarter) stood at $88.7 million in 2021, then dropped by 1.58% to $87.3 million in 2022, then fell by 15.12% to $74.1 million in 2023, then decreased by 24.29% to $56.1 million in 2024, then tumbled by 34.76% to $36.6 million in 2025.
  • Its last three reported values are $36.6 million in Q3 2025, $31.5 million for Q2 2025, and $24.7 million during Q1 2025.